"Calquence plus venetoclax is the first and only all-oral combination treatment option with a second-generation BTK inhibitor ...

AstraZeneca (AZ) has announced that its fixed-duration Calquence (acalabrutinib)-based regimens have been approved by the ...

A fixed-duration regimen of AstraZeneca's Calquence (acalabrutinib) in combination with venetoclax, with or without ...

AstraZeneca (LSE: AZN) has received European approval for a fixed-duration regimen of Calquence (acalabrutinib) in ...

Calquence (acalabrutinib) is a prescription drug approved to treat certain blood cancers, such as chronic lymphocytic leukemia. Calquence comes as an oral tablet. Calquence contains the active ...

Drugmaker AstraZeneca said on Friday that it had received approval from the European Commission for fixed-duration regimens ...

AstraZeneca PLC (LSE/STO/Nasdaq:LON:AZN) announced the European Union’s approval of its fixed-duration Calquence (acalabrutinib) regimens for the treatment of adult patients with previously ...

This trial demonstrated that 77% of subjects treated with Calquence and venetoclax combo and 83% of those who received the therapy along with venetoclax and obinutuzumab remained progression-free ...

AstraZeneca PLC (LSE/STO/Nasdaq:LON:AZN) announced the European Union’s approval of its fixed-duration Calquence (acalabrutinib) regimens for the treatment of adult patients with previously untreated ...